Longboard Pharma's CEO describes today's open label extension data for bexicaserin in Developmental and Epileptic Encephalopathies

Kevin Lind explains how patients randomized to therapy and placebo crossover patients are seeing comparable reductions in seizure levels. He also discusses the regulatory path ahead as this programs looks to enter pivotal study(ies).